Yunnan Botanee Bio-Technology Group

Guo Zhenyu, the founder, Chairman, and General Manager, is the sole actual controller of the group. His holdings are structured through Kunming Nuona Technology onshore and Hanson Cosmeceutical (Hanson BVI) offshore. His son Kevin Guo is no longer an actual controller as of late 2024. Investment decisions are not made by an external CIO—they flow through Guo Zhenyu as the controlling shareholder-operator.

Botanee deploys corporate balance-sheet capital directly. It does not operate as a venture capital or private equity fund, and there is no known external LP base. The group generates investment capital from the cash flows of its Winona skincare brand, which commands leading market share in China's hospital-recommended dermo-cosmetic channel.

Botanee concentrates on the dermatology value chain: functional skincare, dermo-cosmetics, aesthetic medicine technology, and related consumer health categories. Its research centers in Shanghai, Paris, and Japan provide a pipeline for ingredient science and clinical application. The group does not invest outside this domain into unrelated technology or industrial sectors.

Sequoia Capital China was an early institutional investor in Botanee through its Sequoia Juye vehicle, prior to the company's 2021 Shenzhen Stock Exchange listing. This made Sequoia one of the few external shareholders during Botanee's growth phase. Post-IPO, the Guo family regained sole control, and there is no evidence of ongoing co-investment arrangements with Sequoia.

Winona was co-developed with the dermatology department of the First Affiliated Hospital of Kunming Medical University, giving Botanee deep ties to China's hospital dermatology network. This clinical distribution channel informs investment priorities—the group favors assets that can leverage hospital and pharmacy recommendation pathways rather than purely consumer-brand direct-to-consumer models.

The Guo family's wealth originates from the development and scaling of Winona, a dermo-cosmetic brand built on Yunnan plant extraction technology. The brand was founded by Guo Zhenyu, who remains the sole actual controller. The company's 2021 Shenzhen IPO created significant public-market wealth, but the primary asset remains the operating skincare business.

Yes. Botanee operates the Botanee Charity Fund and the Yunnan Red Cross Winona Charity Foundation. Guo Zhenyu also chairs the International Self-Care Foundation and previously chaired the World Self-Medication Industry association, reflecting a broader institutional commitment to self-care and consumer health advocacy beyond commercial activity.